[008] Accordingly, it is an object of the present invention to improve the absorption rate of triptans and other migraine medications when orally administered. Another object is to improve the absorption rate of triptans and other migraine medications when orally administered during a migraine attack.

[009] Yet another object is to treat the symptoms associated with migraine, using a combined drug regimen, to provide relief greater than that achieved using a triptan or other migraine medication alone.

[010] Thus, another object is the provision of a combined drug regimen that treats one or more symptoms often associated with migraine faster than a triptan or other migraine medication alone, wherein said symptoms are selected from nausea, photophobia, phonophobia, pain, and rebound headache.

[011] In another embodiment the combined drug regimen treats one or more symptoms often associated with migraine better than a triptan or other migraine medication alone, wherein said symptoms are selected from nausea, photophobia, phonophobia, pain, and rebound headache.

SUMMARY ~~OF THE INVENTION~~

[012] The present disclosure~~invention~~ relates to a method of treating a subject having a migraine, or preventing a migraine in a subject having a history of migraines or at risk of developing a migraine, by co-administering a ghrelin mimetic of the present disclosure~~invention~~ and a migraine drug, and thereby enhancing the speed of absorption and/or therapeutic effect of the migraine drug.

Thus, in one aspect, there is provided the use of a ghrelin mimetic in the manufacture of a medicament for enhancing the speed of absorption of an anti-migraine medicament in a subject having a migraine.

~~Thus, in~~In one embodiment, the disclosure~~invention~~ provides a method of enhancing the speed of absorption (or speed of therapeutic effect) of a second molecule selected from serotonin 5-$HT_{1B/1D}$ receptor agonists, tryptamine derivatives, ergoline derivatives, non-steroidal anti-inflammatory drugs, and analgesics comprising administering to a subject having a migraine an effective amount of a ghrelin mimetic and the second molecule.

[012a] In another aspect, there is provided the use of a ghrelin mimetic in the manufacture of a medicament for treating a subject having a migraine, wherein said medicament is to be administered with a second molecule selected from serotonin 5-$HT_{1B/1D}$ receptor agonists, tryptamine derivatives, ergoline derivatives, non-steroidal anti-inflammatory drugs, and analgesics.

[013] In another embodiment, the disclosure~~invention~~ provides a method of treating a subject having a migraine comprising administering to the subject an effective amount of a ghrelin mimetic and a second molecule selected from serotonin 5-$HT_{1B/1D}$ receptor agonists, tryptamine derivatives, ergoline derivatives, non-steroidal anti-inflammatory drugs, and analgesics.

[013a] In still another aspect, there is provided the use of a ghrelin mimetic in the manfacture of a medicament for treating the complications or symptoms of migraine in a subject suffering from one or more of said complications or symptoms, wherein said complications or symptoms are selected from gastric stasis, nausea, vomiting, photophobia and phonophobia, and wherein said medicament is to be administered with a second molecule selected from serotonin 5-$HT_{1B/1D}$ receptor agonists, tryptamine derivatives, ergoline derivatives, non-steroidal anti-inflammatory drugs, and analgesics.

[014] In still another embodiment, the disclosure~~invention~~ relates to the treatment, and improved speed of absorption and/or effectiveness, in patients suffering from complications or symptoms of migraine. Therefore, in still another embodiment the disclosure~~invention~~ provides a method of treating one or more complications or symptoms of migraine, and/or enhancing the speed of absorption or therapeutic effect in a patient suffering from such complications or symptoms, wherein said complications or symptoms are selected from gastric stasis, nausea, vomiting, photophobia and phonophobia, comprising administering to a subject suffering from one or more of said complications or symptoms an effective amount of a ghrelin mimetic of the present disclosure~~invention~~ and a second molecule selected from serotonin 5-$HT_{1B/1D}$ receptor agonists, tryptamine derivatives, ergoline derivatives, non-steroidal anti-inflammatory drugs, and analgesics.

[015] The present disclosure~~invention~~ further relates to a method of treating gastrointestinal upset and other conditions caused by a migraine. Gastrointestinal upset includes one or more of the symptoms of gastric stasis, emesis, nausea, or vomiting. The method involves administering to a subject in need thereof a therapeutically effective amount of a ghrelin mimetic of the present disclosure~~invention~~ and at least one additional therapeutic agent, e.g., a serotonin 5-$HT_{1B/1D}$ receptor agonist, a tryptamine derivative, an ergoline derivative, a non-steroidal anti-inflammatory drug, an analgesic, or any combination thereof.

[016] The disclosure~~invention~~ further provides pharmaceutical compositions for the treatment of migraines comprising the ghrelin mimetics of the disclosure~~invention~~ and at least one of a serotonin 5-HT1B/1D receptor agonist, a tryptamine derivative, an ergoline derivative, a non-steroidal anti-inflammatory drug, an analgesic, or any combination thereof.

[016a] In another aspect, there is provided a pharmaceutical composition for the treatment of migraine, comprising an effective amount of a ghrelin mimetic and a second molecule, wherein the second molecule is selected from the group consisting of serotonin 5-$HT_{1B/1D}$ receptor agonists, tryptamine derivatives, ergoline derivatives, non-steroidal anti-inflammatory drugs, and analgesics.

[017] The foregoing and other objects, features and advantages of the disclosure~~invention~~ will be apparent from the following more particular description of preferred embodiments of the disclosure~~invention~~.

DETAILED DESCRIPTION OF THE INVENTION

[018] The present invention may be understood more readily by reference to the following detailed description of preferred embodiments of the invention and the Examples included therein.